Third Quarter Revenues Increase 36% to $11.0Million U.S. WatchPATTMRevenues Increase 55% to $8.9Million Full Year 2020 Revenue Guidance of $39.5 Million to $40.5 Million Company to Host Conference Call Today at 8:00am ET, 3:00pm IT CAESAREA, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical […]
Other News
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]
Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation
MARLBOROUGH, Mass., Nov. 17, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system. The voluntary recall is related solely to the delivery system, as the valve […]
Late-Breaking Study Results of the Supreme HT™ Healing-Targeted DES Demonstrated Equivalent Outcomes with Exceptional Safety
TIANJIN, China, Nov. 17, 2020 /PRNewswire/ — SINOMED® today announced that Prof. Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent, to the Xience or Promus Durable Polymer Drug-Eluting Stent (DP DES). One-year results, revealed […]
INFINITY ANGIOPLASTY BALLOON CATHETER™ Completes First-In-Human PRECISION ANGIOPLASTY™
TOLEDO, Ohio, Nov. 17, 2020 /PRNewswire/ — INFINITY ANGIOPLASTY BALLOON CO., announced today that its innovative PRECISION ANGIOPLASTY™ balloon platform – INFINITY ANGIOPLASTY BALLOON CATHETER™ has successfully completed First-in-Human clinical trial. Recently cleared by the FDA for PTA treatment of peripheral artery disease including: iliac femoral popliteal infra-popliteal arteries for the treatment of […]
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions […]
SANUWAVE Health Reports Third Quarter 2020 Financial Results
Transformational Acquisition Positions for Significant Growth in Fourth Quarter 2020 and Beyond SUWANEE, GA, Nov. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, […]
Biotricity Reports Results for the Quarter Ended September 30, 2020
Revenues grow 64.8% over the immediately preceding quarter and a 115.3% increase over the corresponding period of the prior year Loss per share of 8.5 cents in line with levels of immediately preceding quarter REDWOOD CITY, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and […]
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary […]
Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes
Late-breaking data presented at AHA 2020 Scientific Sessions and published simultaneously in Circulation WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, reduced the risk of cardiovascular (CV) outcomes in patients with […]



